Familial juvenile hypertrophy of the breast

Summary

Familial juvenile hypertrophy of the breast (MONDO:0007237) is a disease. A subtype of breast disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	familial juvenile hypertrophy of the breast
Mondo ID	MONDO:0007237
MeSH	C536821
OMIM	113670
Orphanet	180176
UMLS	C0405471
MedGen	140798
GARD	0009450
Is cancer (heuristic)	no

Also known as: familial juvenile gigantomastia · hypertrophy of the breast, juvenile · JHB · juvenile gigantomastia · juvenile macromastia · virginal breast hypertrophy · virginal mammary hypertrophy

Disease family

This is a subtype of breast disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › breast disorder › familial juvenile hypertrophy of the breast

Related subtypes (14): breast abscess, hypertrophy of breast, fat necrosis of breast, breast angiomatosis, breast adenosis, benign mammary dysplasia, breast fibrocystic disease, mastitis, supernumerary breasts, isolated congenital breast hypoplasia/aplasia, syndromic breast hypoplasia/aplasia, breast neoplasm, lactation disease, breast implant illness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.